Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 1
1980 2
1982 4
1983 2
1985 4
1986 1
1987 4
1988 1
1989 4
1990 2
1991 6
1992 4
1993 3
1994 9
1995 3
1996 8
1997 7
1998 4
1999 4
2000 4
2001 6
2002 7
2003 9
2004 9
2005 9
2006 8
2007 5
2008 7
2009 8
2010 11
2011 13
2012 11
2013 15
2014 7
2015 9
2016 16
2017 20
2018 21
2019 16
2020 19
2021 24
2022 27
2023 167
2024 35

Text availability

Article attribute

Article type

Publication date

PubMed for id: 355856

500 results

Results by year

Filters applied: . Clear all
Page 1
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network). Anderson KC, et al. J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9. doi: 10.6004/jnccn.2012.0128. J Natl Compr Canc Netw. 2012. PMID: 23054875
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E. D'Sa S, et al. Semin Hematol. 2023 Mar;60(2):80-89. doi: 10.1053/j.seminhematol.2023.03.003. Epub 2023 Mar 27. Semin Hematol. 2023. PMID: 37147252
Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, Liu T, Song YP, Xu B, Zhu ZM, Xu W, Zhang MZ, Tian YM, Zhang B, Zhao RB, Zhou DB. Cao XX, et al. EClinicalMedicine. 2022 Oct 4;52:101682. doi: 10.1016/j.eclinm.2022.101682. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 36313145 Free PMC article.
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Deng J, Paulus A, Fang DD, Manna A, Wang G, Wang H, Zhu S, Chen J, Min P, Yin Y, Dutta N, Halder N, Ciccio G, Copland JA, Miller J, Han B, Bai L, Liu L, Wang M, McEachern D, Przybranowski S, Yang CY, Stuckey JA, Wu D, Li C, Ryan J, Letai A, Ailawadhi S, Yang D, Wang S, Chanan-Khan A, Zhai Y. Deng J, et al. Clin Cancer Res. 2022 Dec 15;28(24):5455-5468. doi: 10.1158/1078-0432.CCR-21-4037. Clin Cancer Res. 2022. PMID: 36048524
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.
Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P, Phetsouphanh C, Warden A, Klemm V, Munier CML, Hoppe AC, Tea F, Pillay A, Stella AO, Aggarwal A, Lavee O, Caterson ID, Turville S, Kelleher AD, Brilot F, Trotman J. Beaton B, et al. Am J Hematol. 2023 Jan;98(1):131-139. doi: 10.1002/ajh.26619. Epub 2022 Jun 9. Am J Hematol. 2023. PMID: 35607995 Free PMC article.
500 results